Table 3 Clinical characteristics over time
Time point | Total N (%) | Intervention N (%) | Standard of care N (%) | p-value* | |
|---|---|---|---|---|---|
Viral load (log10 copies/ml) Median(IQR) | Baseline | 4.3 (3.7–4.8) | 4.2 (3.6–4.7) | 4.5 (3.8–4.9) | |
Week 12 | 3.9 (2.2–4.6) | 3.6 (2.0–4.4) | 4.1 (2.7–4.7) | 0.041* | |
Week 24 | 3.6 (2.0–4.5) | 3.2 (1.5–4.5) | 3.8 (2.3–4.5) | 0.111 | |
Week 36 | 3.1 (0.0–4.6) | 2.7 (0–4.5) | 3.4 (1.7–4.6) | 0.113 | |
Viral load ≥ 1000 copies/mL n (%) | Baseline | 200 (94.3%) | 183 (86.3%) | 89 (85.6%) | |
Week 12 | 193 (91.0%) | 92 (88.5%) | 101 (93.5%) | 0.198 | |
Week 24 | 175 (82.6%) | 79 (76.0%) | 96 (89.0%) | 0.013* | |
Week 36 | 157 (74.1%) | 71 (68.3%) | 86 (79.6%) | 0.059 | |
Self-reported adherence (95% or higher), n (%) | Baseline | 134 (74.4%) | 61 (67.8%) | 73 (81.1%) | |
Week 12 | 144 (68.3%) | 70 (67.3%) | 74 (69.2%) | 0.773 | |
Week 24 | 140 (68.0%) | 68 (66.7%) | 72 (69.2%) | 0.693 | |
Week 36 | 139 (67.5%) | 68 (66.0%) | 71 (68.9%) | 0.655 |